STOCK TITAN

PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

Welcome to our dedicated page for PETVIVO HOLDINGS WTS news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS WTS stock.

PETVIVO HOLDINGS INC WTS (symbol: PETVW) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. With a strategic approach of leveraging investments in human biomaterials and medical device industries, PETVIVO aims to bring therapeutics to pets in a capital and time-efficient manner. The company's core strategy involves in-licensing proprietary products from human medical device companies for pet use. PETVIVO HOLDINGS INC WTS is the parent company of petvivo, inc, gel-del technologies, inc, and cosmetalife corporation.

Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announces its participation in the Veterinary Meeting & Expo Conference from January 15-19, 2022, in Orlando, FL. The company will showcase its lead product, Spryng with OsteoCushion Technology, designed to treat joint issues in pets, particularly osteoarthritis. With over 7,500 expected participants, the event presents an opportunity for PetVivo to network with industry leaders. The company's product is set for expanded commercial sales in Q4 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced a distribution agreement with VetCove, Inc. to market its therapeutic product, SPRYNG™ with OsteoCushion™ Technology. VetCove, utilized by over 13,000 veterinary hospitals, will enable easier access for veterinarians to order SPRYNG for pets suffering from osteoarthritis. This innovative device, comprised of micronized hydrogel matrices, aims to support joint health and alleviates lameness. PetVivo also holds a diverse pipeline of products, enhancing its position in the veterinary market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO John Lai will discuss the company's business overview on January 10 at 12:00 PM EST. PetVivo focuses on innovative medical devices for pets, including its lead product, SPRYNG, which targets joint issues in animals. The company holds 21 patents and plans for expanded commercial sale of SPRYNG in Q4 2022. For more details, visit PetVivo's official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a successful showcase of its product, Spryng, at the American Association of Equine Practitioners (AAEP) conference from December 4-8, 2021. Spryng utilizes OsteoCushion Technology for treating lameness and joint issues like osteoarthritis. The company received positive feedback from veterinarians, indicating strong interest in adopting Spryng. PetVivo is offering a promotional deal through December 31, 2021, providing an extra syringe for every five purchased. The company plans expanded sales of Spryng in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV) will participate in the American Association Equine Practitioners (AAEP) conference from December 4-8, 2021, in Nashville, TN. The company aims to showcase its lead product, SPRYNG, featuring OsteoCushion Technology, designed to treat lameness and joint issues, including osteoarthritis, in pets. The AAEP conference is expected to draw over 5,000 industry professionals, presenting opportunities for networking and business development. The company plans to expand commercial sales of SPRYNG in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

PetVivo Holdings announces a comprehensive digital media campaign to promote its product Spryng™, targeting improvements in animal lameness. The campaign includes 40 interviews and 600 T.V. commercials over the next year on major networks like Newsmax and Bloomberg. Additionally, 2,400 digital billboard ads will be displayed daily in Manhattan. Spryng™, which aids osteoarthritis in pets, is set for expanded sales this quarter. PetVivo aims to leverage veterinary opportunities similar to human therapies, supported by a robust patent portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

PetVivo Holdings raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ as Spryng™ and initiating sales. In Q2 2022, revenue reached $4,977, up from $4,790 in Q2 2021. The company reported a net loss of $1,105,474, improved from $1,348,002 in the same period last year. For the six months ended September 30, 2021, revenue was $9,122. The company aims to utilize offering proceeds to enhance sales and marketing efforts and has made key management hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ to Spryng™. As of September 30, 2021, revenues increased to $4,977 for Q2 2021 from $4,790 in Q2 2020. Net loss decreased to ($1,105,474) compared to ($1,348,002) year-over-year. Significant investments in sales, marketing, and research were made to support the launch of Spryng™. Key management hires were also announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

PetVivo Holdings, Inc. will release its financial results for Q2 FY 2022 on November 15, 2021, post-market. A conference call is scheduled for 4:00 p.m. CT to discuss these results. The call will be available via webcast on their Investor Relations website. PetVivo focuses on innovative medical devices for animals, leveraging human therapies to expedite market entry. They have a pipeline of 17 products and 21 patents, with their lead product, SPRYNG™, aimed at treating osteoarthritis in dogs and horses, set for expanded sales this quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

PetVivo Holdings closed its public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit comprises one common stock share and a warrant to purchase one share at $5.625, exercisable immediately for five years. The offering, which included an over-allotment option of 375,000 warrants exercised by the underwriter, supports marketing, R&D, and debt repayment. The stock began trading on Nasdaq under the symbols PETV and PETVW on August 11, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of PETVIVO HOLDINGS WTS (PETVW)?

The current stock price of PETVIVO HOLDINGS WTS (PETVW) is $0.0295 as of December 24, 2024.

What does PETVIVO HOLDINGS INC WTS specialize in?

PETVIVO focuses on licensing and commercializing innovative medical devices for pets, also known as pet therapeutics.

What is PETVIVO's strategic approach?

The company leverages investments in human biomaterials and medical device industries to efficiently bring therapeutics to pets.

How does PETVIVO commercialize products for pets?

PETVIVO in-licenses proprietary products from human medical device companies specifically for pet use.

What subsidiaries are under PETVIVO HOLDINGS INC?

petvivo, inc, gel-del technologies, inc, and cosmetalife are all wholly-owned subsidiaries of PETVIVO HOLDINGS INC.

What is PETVIVO's core business model?

PETVIVO's core model involves commercializing innovative medical devices for pets through strategic partnerships.

What is the significance of PETVIVO in the biomedical device industry?

PETVIVO plays a crucial role by bringing human medical advancements to the pet therapeutics sector.

How does PETVIVO ensure efficient commercialization of pet therapeutics?

PETVIVO's strategy focuses on in-licensing products from human medical device companies, streamlining the process.

What sets PETVIVO apart in the pet therapeutics market?

PETVIVO's unique approach of leveraging human medical device technology for pets sets it apart in the industry.

What are some recent achievements of PETVIVO HOLDINGS INC WTS?

PETVIVO has successfully partnered with leading human medical device companies to bring cutting-edge therapeutics to pets.

What can investors expect from PETVIVO's future projects?

Investors can anticipate further advancements in pet therapeutics through PETVIVO's ongoing projects and collaborations.

PETVIVO HOLDINGS INC WTS

Nasdaq:PETVW

PETVW Rankings

PETVW Stock Data

Medical Devices
Healthcare
Link
United States of America
Edina